Eli Lilly jettisons cancer contender after another Phase III failure

Ryan McBride The Indianapolis-based drug giant has slammed the brakes on development of enzastaurin, which failed to meet the main goal for boosting disease-free survival in a Phase ...

Lilly CEO set for surgery on dilated aorta; CFO steps up temporarily

Tracy Staton Eli Lilly Chairman and CEO John Lechleiter is scheduled for surgery for a dilated aorta on Monday and will hand the CEO reins over to CFO Derica Rice as he recovers. If ...

Lilly to slash 1,624 sales jobs in stepped-up layoff plan

Tracy Staton As the Indianapolis Business Journal reports, the drugmaker now plans to eliminate 1,624 sales positions, rather than the "fewer than 1,000" cuts previously announced. ...

Eli Lilly slugs it out with J&J on Alzheimer’s drug patent claim

John Carroll With a new late-stage study being prepped for the Alzheimer's drug solanezumab, Eli Lilly found itself in a London courtroom this week defending itself against a patent ...

Lilly cost-cutting and price hikes pay off with Q1 earnings beat

Tracy Staton The moral of Eli Lilly's first-quarter performance is this: Raise prices and cut costs. The drugmaker ($ LLY) beat analyst expectations on earnings, partly because ...

Eli Lilly rolls the dice on combo approach against Alzheimer’s disease

Ryan McBride Undeterred by its past failures in the Alzheimer's field, Eli Lilly ($ LLY) has invested more in research of drugs that target tangles of tau in the brains of patients ...

Eli Lilly scores upbeat PhIII data for GLP1 drug in busy diabetes market

Ryan McBride Eli Lilly ($ LLY) has added to a body of positive Phase III data for its once-weekly GLP-1 candidate dulaglutide, with two more late-stage studies that have met their ...

Lilly settles long-running lawsuit tying Cymbalta to teen’s suicide

Eric Palmer Eli Lilly ($ LLY) has battled to protect its best-selling drug, the antidepressant Cymbalta, against generic competition but has decided not to stand and fight a lawsuit ...

Bristol-Myers, Lilly expand biologics operations

Eric Palmer Biologic drugs make up a growing part of drugmakers' pipelines and pharma is putting hundreds of millions into infrastructure in preparation for that future. Eli Lilly ...

Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliff

Here is a business reality that hundreds of Eli Lilly ($ LLY) sales employees are going to have to align themselves with quite soon: They are about to lose their jobs. With its best-selling ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS